International Journal of Hematology

, Volume 91, Issue 4, pp 557–568

Molecular mechanisms underlying deregulation of C/EBPα in acute myeloid leukemia

Review Article

Abstract

The CEBPA gene encodes a transcription factor protein that is crucial for granulocytic differentiation, regulation of myeloid gene expression and growth arrest. Mutations in one or both alleles of CEBPA are observed in about 10% of patients with acute myeloid leukemia (AML). Moreover, other genetic events associated with AML have been identified to deregulate C/EBPα expression and function at various levels. Recently developed mouse models that accurately mimic the genetic C/EBPα alterations in human AML demonstrate C/EBPα’s gatekeeper function in the control of self-renewal and lineage commitment of hematopoietic stem cells (HSCs). Moreover, these studies indicate that CEBPA mutations affect HSCs in early leukemia development by inducing proliferation and limiting their lineage potential. However, the exact relationship between ‘pre-leukemic’ HCSs and those cells that finally initiate leukemia (leukemia-initiating cells) with disturbed differentiation and aberrant proliferation remains elusive. More research is needed to identify and characterize these functionally distinct populations and the exact role of the different genetic alterations in the process of leukemia initiation and maintenance.

Keywords

AML Leukemia Transcription factor C/EBPα Myeloid differentiation Bi-allelic mutation 

References

  1. 1.
    Virchow R. Weisses blut. Frorieps Notizen 1845;36:151–6.Google Scholar
  2. 2.
    Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003;3(2):89–101.CrossRefPubMedGoogle Scholar
  4. 4.
    Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol. 2007;7(2):105–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Tenen DG, et al. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90(2):489–519.PubMedGoogle Scholar
  6. 6.
    Rosmarin AG, Yang Z, Resendes KK. Transcriptional regulation in myelopoiesis: hematopoietic fate choice. Myeloid differentiation, and leukemogenesis. Exp Hematol. 2005;33(2):131–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Pabst T, Mueller BU. Transcriptional dysregulation during myeloid transformation in AML. Oncogene. 2007;26(47):6829–37.CrossRefPubMedGoogle Scholar
  8. 8.
    Landschulz WH, et al. Isolation of a recombinant copy of the gene encoding C/EBP. Genes Dev. 1988;2(7):786–800.CrossRefPubMedGoogle Scholar
  9. 9.
    Akira S, et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 1990;9(6):1897–906.PubMedGoogle Scholar
  10. 10.
    Roman C, et al. Ig/EBP-1: a ubiquitously expressed immunoglobulin enhancer binding protein that is similar to C/EBP and heterodimerizes with C/EBP. Genes Dev. 1990;4(8):1404–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Cleutjens CB, et al. The human C/EBP delta (CRP3/CELF) gene: structure and chromosomal localization. Genomics. 1993;16(2):520–3.CrossRefPubMedGoogle Scholar
  12. 12.
    Antonson P, et al. A novel human CCAAT/enhancer binding protein gene, C/EBPepsilon, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor alpha/delta locus. Genomics. 1996;35(1):30–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Park JS, et al. Isolation, characterization and chromosomal localization of the human GADD153 gene. Gene. 1992;116(2):259–67.CrossRefPubMedGoogle Scholar
  14. 14.
    Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002;365(Pt 3):561–75.PubMedGoogle Scholar
  15. 15.
    Miller M, et al. Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha. J Biol Chem. 2003;278(17):15178–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang ND, et al. Impaired energy homeostasis in C/EBP alpha knockout mice. Science. 1995;269(5227):1108–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang DE, et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA. 1997;94(2):569–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Lin FT, et al. A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity. Proc Natl Acad Sci USA. 1993;90(20):9606–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Kaufman RJ. Regulation of mRNA translation by protein folding in the endoplasmic reticulum. Trends Biochem Sci. 2004;29(3):152–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Calkhoven CF, Muller C, Leutz A. Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev. 2000;14(15):1920–32.PubMedGoogle Scholar
  21. 21.
    Nerlov C, Ziff EB. CCAAT/enhancer binding protein-alpha amino acid motifs with dual TBP and TFIIB binding ability co-operate to activate transcription in both yeast and mammalian cells. EMBO J. 1995;14(17):4318–28.PubMedGoogle Scholar
  22. 22.
    Johansen LM, et al. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol. 2001;21(11):3789–806.CrossRefPubMedGoogle Scholar
  23. 23.
    Porse BT, et al. E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo. Cell. 2001;107(2):247–58.CrossRefPubMedGoogle Scholar
  24. 24.
    Cleaves R, Wang QF, Friedman AD. C/EBPalphap30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding. Oncogene. 2004;23(3):716–25.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang H, et al. C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell. 2001;8(4):817–28.CrossRefPubMedGoogle Scholar
  26. 26.
    Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol. 1995;11:35–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Orkin SH. Diversification of haematopoietic stem cells to specific lineages. Nat Rev Genet. 2000;1(1):57–64.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang P, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 2004;21(6):853–63.CrossRefPubMedGoogle Scholar
  29. 29.
    Heath V, et al. C/EBPalpha deficiency results in hyperproliferation of hematopoietic progenitor cells and disrupts macrophage development in vitro and in vivo. Blood. 2004;104(6):1639–47.CrossRefPubMedGoogle Scholar
  30. 30.
    Suh HC, et al. C/EBPalpha determines hematopoietic cell fate in multipotential progenitor cells by inhibiting erythroid differentiation and inducing myeloid differentiation. Blood. 2006;107(11):4308–16.CrossRefPubMedGoogle Scholar
  31. 31.
    Radomska HS, et al. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol. 1998;18(7):4301–14.PubMedGoogle Scholar
  32. 32.
    Zhang P, et al. Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis. J Exp Med. 1998;188(6):1173–84.CrossRefPubMedGoogle Scholar
  33. 33.
    Liu F, et al. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity. 1996;5(5):491–501.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhang P, et al. Induction of granulocytic differentiation by 2 pathways. Blood. 2002;99(12):4406–12.CrossRefPubMedGoogle Scholar
  35. 35.
    Umek RM, Friedman AD, McKnight SL. CCAAT-enhancer binding protein: a component of a differentiation switch. Science. 1991;251(4991):288–92.CrossRefPubMedGoogle Scholar
  36. 36.
    Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004;4(5):394–400.CrossRefPubMedGoogle Scholar
  37. 37.
    Leroy H, et al. CEBPA point mutations in hematological malignancies. Leukemia. 2005;19(3):329–34.CrossRefPubMedGoogle Scholar
  38. 38.
    Preudhomme C, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100(8):2717–23.CrossRefPubMedGoogle Scholar
  39. 39.
    Gombart AF, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood. 2002;99(4):1332–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Kaeferstein A, et al. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. Leukemia. 2003;17(2):343–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Tiesmeier J, et al. Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia. Br J Haematol. 2003;123(3):413–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Frohling S, et al. Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosom Cancer. 2005;42(4):427–32.CrossRefPubMedGoogle Scholar
  43. 43.
    Snaddon J, et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosom Cancer. 2003;37(1):72–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Barjesteh van Waalwijk van Doorn-Khosrovani S et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J. 2003;4(1):31–40.Google Scholar
  45. 45.
    Frohling S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22(4):624–33.CrossRefPubMedGoogle Scholar
  46. 46.
    Bienz M, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005;11(4):1416–24.CrossRefPubMedGoogle Scholar
  47. 47.
    Pabst T, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27(3):263–70.CrossRefPubMedGoogle Scholar
  48. 48.
    Haferlach T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology. 2008;2008(1):400–11.CrossRefGoogle Scholar
  49. 49.
    Pabst T, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 2001;7(4):444–51.CrossRefPubMedGoogle Scholar
  50. 50.
    Heidenreich O, et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood. 2003;101(8):3157–63.CrossRefPubMedGoogle Scholar
  51. 51.
    Lin LI, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005;11(4):1372–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Kirstetter P, et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell. 2008;13(4):299–310.CrossRefPubMedGoogle Scholar
  53. 53.
    Shih LY, et al. AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2006;20(4):604–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Valk PJ, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617–28.CrossRefPubMedGoogle Scholar
  55. 55.
    Wouters BJ, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood. 2007;110(10):3706–14.CrossRefPubMedGoogle Scholar
  56. 56.
    Pabst T, et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer. 2009;100(8):1343–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Wouters BJ, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088–91.CrossRefPubMedGoogle Scholar
  58. 58.
    Schlenk RF, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–18.CrossRefPubMedGoogle Scholar
  59. 59.
    Sellick GS, et al. Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia. 2005;19(7):1276–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Pabst T, et al. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol. 2008;26(31):5088–93.CrossRefPubMedGoogle Scholar
  61. 61.
    Smith ML, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351(23):2403–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Schwieger M, et al. A dominant-negative mutant of C/EBPalpha, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse. Blood. 2004;103(7):2744–52.CrossRefPubMedGoogle Scholar
  63. 63.
    Cammenga J, et al. Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells. Blood. 2003;101(6):2206–14.CrossRefPubMedGoogle Scholar
  64. 64.
    Geletu M, et al. Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9. Blood. 2007;110(9):3301–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Wagner K, et al. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci USA. 2006;103(16):6338–43.CrossRefPubMedGoogle Scholar
  66. 66.
    Porse BT, et al. Loss of C/EBP alpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage. J Exp Med. 2005;202(1):85–96.CrossRefPubMedGoogle Scholar
  67. 67.
    Bereshchenko O, et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell. 2009;16(5):390–400.CrossRefPubMedGoogle Scholar
  68. 68.
    Kelly LM, et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99(1):310–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Cammenga J. Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML. Leukemia. 2005;19(10):1719–28.CrossRefPubMedGoogle Scholar
  70. 70.
    Shih LY, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387–92.CrossRefPubMedGoogle Scholar
  71. 71.
    Haferlach T, et al. Genetic classification of acute myeloid leukemia (AML). Ann Hematol. 2004;83(Suppl 1):S97–100.PubMedGoogle Scholar
  72. 72.
    Skokowa J, et al. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med. 2006;12(10):1191–7.CrossRefPubMedGoogle Scholar
  73. 73.
    Helbling D, et al. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proc Natl Acad Sci USA. 2004;101(36):13312–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Helbling D, et al. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood. 2005;106(4):1369–75.CrossRefPubMedGoogle Scholar
  75. 75.
    Chang JS, et al. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood. 2007;110(3):994–1003.CrossRefPubMedGoogle Scholar
  76. 76.
    Perrotti D, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30(1):48–58.CrossRefPubMedGoogle Scholar
  77. 77.
    Scheuner D, et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell. 2001;7(6):1165–76.CrossRefPubMedGoogle Scholar
  78. 78.
    Assouline S, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009;114(2):257–60.CrossRefPubMedGoogle Scholar
  79. 79.
    Koschmieder S, et al. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007;110(10):3695–705.CrossRefPubMedGoogle Scholar
  80. 80.
    Keeshan K, et al. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell. 2006;10(5):401–11.CrossRefPubMedGoogle Scholar
  81. 81.
    Ross SE, et al. Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol. 2004;24(2):675–86.CrossRefPubMedGoogle Scholar
  82. 82.
    Radomska HS, et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med. 2006;203(2):371–81.CrossRefPubMedGoogle Scholar
  83. 83.
    Trivedi AK, et al. Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPalpha by inhibiting its ubiquitination. Oncogene. 2007;26(12):1789–801.CrossRefPubMedGoogle Scholar
  84. 84.
    Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.CrossRefPubMedGoogle Scholar
  85. 85.
    Truong BT, et al. CCAAT/enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood. 2003;101(3):1141–8.CrossRefPubMedGoogle Scholar
  86. 86.
    Ferrari-Amorotti G, et al. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha. Blood. 2006;108(4):1353–62.CrossRefPubMedGoogle Scholar
  87. 87.
    Schepers H, et al. Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007;110(4):1317–25.CrossRefPubMedGoogle Scholar
  88. 88.
    Lapidot T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–8.CrossRefPubMedGoogle Scholar
  89. 89.
    Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  1. 1.Department of Molecular Medicine and Gene Therapy, Lund Stem Cell CenterLund UniversityLundSweden
  2. 2.Department of HematologyLund UniversityLundSweden

Personalised recommendations